Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
25 September 2020Website:
http://www.geovax.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
regular market | 8 min agoDividend
Analysts recommendations
Institutional Ownership
GOVX Latest News
Biotechnology specialist GeoVax (NASDAQ: GOVX ) — which focuses on developing immunotherapies and vaccines against cancers and infectious diseases — just announced a partnership with global clinical research organization Allucent. The main purpose behind the agreement is to conduct a Phase 2b clinical trial of GeoVax's next-generation Covid-19 vaccine.
GeoVax Labs, Inc. (NASDAQ:GOVX) will be hosting its Q1 2024 Earnings Conference Call on May 14, 2024 at 4:30 PM ET. Company representatives Max Gadicke, David Dodd, Mark Reynolds, Kelly McKee, and John Sharkey will be present. The call will be moderated by Mark.
ATLANTA, GA, March 28, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chief Scientific Officer, Mark Newman, PhD, will present data on GEO-CM04S1, the Company's next-generation Covid-19 vaccine candidate, during the upcoming 24th Annual World Vaccine Congress taking place in Washington, DC on April 1-4, 2024.
GeoVax Labs, Inc. (GOVX) Q4 2023 Earnings Call Transcript
ATLANTA, GA, Dec. 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that David Dodd, Chief Executive Officer, will present at the Biotech Showcase coinciding with the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, January 8-11, 2024.
GeoVax Labs, Inc. (GOVX) Q3 2023 Earnings Call Transcript
GeoVax to Host Second Quarter 2023 Conference Call at 4:30 PM ET ATLANTA, GA, July 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, announced today that it will report second quarter 2023 financial results on Wednesday, August 9, 2023, after the market closes. Following the release, management will host a live conference call and webcast to provide a general business update and discuss financial results.
GeoVax Labs, Inc. (NASDAQ:GOVX ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Gabby DeGravina - Investor Relations David Dodd - Chairman and Chief Executive Officer Mark Reynolds - Chief Financial Officer Mark Newman - Chief Scientific Officer Kelly McKee - Chief Medical Officer John Sharkey - Vice President, Business Development Conference Call Participants Jason Kolbert - Dawson James Vernon Bernardino - H.C. Wainwright Kumar Raja - Roth Capital Robert LeBoyer - Noble Capital Markets Operator Good afternoon and welcome everyone to the GeoVax First Quarter 2023 Corporate Update Call.
GeoVax Labs, Inc. (NASDAQ:GOVX ) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ET Company Participants Gabrielle DeGravina - CG Capital David Dodd - Chairman, President & CEO Mark Reynolds - CFO Kelly McKee - Chief Medical Officer Mark Newman - Chief Scientific Officer John Sharkey - Head of Business Development Conference Call Participants Jason Kolbert - Dawson James Securities Vernon Bernardino - H.C. Wainwright & Co. Joanne Lee - Maxim Group Robert LeBoyer - Noble Capital Kumar Raja - ROTH Capital Jeffrey Kraws - Crystal Research Associates Operator Good afternoon and welcome everyone to the GeoVax Fourth Quarter and Full Year 2022 Corporate Update Call.
What type of business is GeoVax Labs?
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
What sector is GeoVax Labs in?
GeoVax Labs is in the Healthcare sector
What industry is GeoVax Labs in?
GeoVax Labs is in the Biotechnology industry
What country is GeoVax Labs from?
GeoVax Labs is headquartered in United States
When did GeoVax Labs go public?
GeoVax Labs initial public offering (IPO) was on 25 September 2020
What is GeoVax Labs website?
https://www.geovax.com
Is GeoVax Labs in the S&P 500?
No, GeoVax Labs is not included in the S&P 500 index
Is GeoVax Labs in the NASDAQ 100?
No, GeoVax Labs is not included in the NASDAQ 100 index
Is GeoVax Labs in the Dow Jones?
No, GeoVax Labs is not included in the Dow Jones index
When does GeoVax Labs report earnings?
Next earnings report date is not announced yet